mirror of
https://github.com/soapingtime/diyhrt.git
synced 2026-03-23 07:36:38 +00:00
[automated] update transfemscience
This commit is contained in:
github-actions
parent
e197ed9e4d
commit
b353d99699
8 changed files with 16 additions and 14 deletions
File diff suppressed because one or more lines are too long
File diff suppressed because one or more lines are too long
File diff suppressed because one or more lines are too long
File diff suppressed because one or more lines are too long
File diff suppressed because one or more lines are too long
File diff suppressed because one or more lines are too long
|
|
@ -1 +1 @@
|
|||
<?xml version="1.0" encoding="utf-8"?><feed xmlns="http://www.w3.org/2005/Atom" ><generator uri="https://jekyllrb.com/" version="3.10.0">Jekyll</generator><link href="https://transfemscience.org/feed-posts.xml" rel="self" type="application/atom+xml" /><link href="https://transfemscience.org/" rel="alternate" type="text/html" /><updated>2025-08-21T14:43:41-07:00</updated><id>https://transfemscience.org/feed-posts.xml</id><title type="html">Transfeminine Science</title><subtitle>Transfeminine Science is a site for information on hormone therapy for transfeminine people.</subtitle><author><name>Transfeminine Science</name></author></feed>
|
||||
<?xml version="1.0" encoding="utf-8"?><feed xmlns="http://www.w3.org/2005/Atom" ><generator uri="https://jekyllrb.com/" version="3.10.0">Jekyll</generator><link href="https://transfemscience.org/feed-posts.xml" rel="self" type="application/atom+xml" /><link href="https://transfemscience.org/" rel="alternate" type="text/html" /><updated>2025-08-26T19:03:55-07:00</updated><id>https://transfemscience.org/feed-posts.xml</id><title type="html">Transfeminine Science</title><subtitle>Transfeminine Science is a site for information on hormone therapy for transfeminine people.</subtitle><author><name>Transfeminine Science</name></author></feed>
|
||||
|
|
@ -1,4 +1,4 @@
|
|||
<?xml version="1.0" encoding="utf-8"?><feed xmlns="http://www.w3.org/2005/Atom" ><generator uri="https://jekyllrb.com/" version="3.10.0">Jekyll</generator><link href="https://transfemscience.org/feed.xml" rel="self" type="application/atom+xml" /><link href="https://transfemscience.org/" rel="alternate" type="text/html" /><updated>2025-08-21T14:43:41-07:00</updated><id>https://transfemscience.org/feed.xml</id><title type="html">Transfeminine Science | Articles</title><subtitle>Transfeminine Science is a site for information on hormone therapy for transfeminine people.</subtitle><author><name>Transfeminine Science</name></author><entry><title type="html">Puberty Blockers: A Review of GnRH Analogues in Transgender Youth</title><link href="https://transfemscience.org/articles/puberty-blockers/" rel="alternate" type="text/html" title="Puberty Blockers: A Review of GnRH Analogues in Transgender Youth" /><published>2022-01-30T15:04:00-08:00</published><updated>2022-01-31T00:00:00-08:00</updated><id>https://transfemscience.org/articles/puberty-blockers</id><content type="html" xml:base="https://transfemscience.org/articles/puberty-blockers/"><![CDATA[<h1 id="puberty-blockers-a-review-of-gnrh-analogues-in-transgender-youth">Puberty Blockers: A Review of GnRH Analogues in Transgender Youth</h1>
|
||||
<?xml version="1.0" encoding="utf-8"?><feed xmlns="http://www.w3.org/2005/Atom" ><generator uri="https://jekyllrb.com/" version="3.10.0">Jekyll</generator><link href="https://transfemscience.org/feed.xml" rel="self" type="application/atom+xml" /><link href="https://transfemscience.org/" rel="alternate" type="text/html" /><updated>2025-08-26T19:03:55-07:00</updated><id>https://transfemscience.org/feed.xml</id><title type="html">Transfeminine Science | Articles</title><subtitle>Transfeminine Science is a site for information on hormone therapy for transfeminine people.</subtitle><author><name>Transfeminine Science</name></author><entry><title type="html">Puberty Blockers: A Review of GnRH Analogues in Transgender Youth</title><link href="https://transfemscience.org/articles/puberty-blockers/" rel="alternate" type="text/html" title="Puberty Blockers: A Review of GnRH Analogues in Transgender Youth" /><published>2022-01-30T15:04:00-08:00</published><updated>2022-01-31T00:00:00-08:00</updated><id>https://transfemscience.org/articles/puberty-blockers</id><content type="html" xml:base="https://transfemscience.org/articles/puberty-blockers/"><![CDATA[<h1 id="puberty-blockers-a-review-of-gnrh-analogues-in-transgender-youth">Puberty Blockers: A Review of GnRH Analogues in Transgender Youth</h1>
|
||||
|
||||
<!-- Supports up to four authors per article currently (author, author2, author3, author4) -->
|
||||
|
||||
|
|
@ -4829,13 +4829,13 @@ Figure 5. Meta-analysis of estradiol concentration-time data from cisgender wome
|
|||
<li>Quaynor, S. D., Stradtman, E. W., Kim, H., Shen, Y., Chorich, L. P., Schreihofer, D. A., & Layman, L. C. (2013). Delayed Puberty and Estrogen Resistance in a Woman with Estrogen Receptor α Variant. <em>New England Journal of Medicine</em>, <em>369</em>(2), 164–171. [DOI:<a href="https://doi.org/10.1056/nejmoa1303611">10.1056/nejmoa1303611</a>]</li>
|
||||
<li>Rinaldi, S., Geay, A., Déchaud, H., Biessy, C., Zeleniuch-Jacquotte, A., Akhmedkhanov, A., Shore, R. E., Riboli, E., Toniolo, P., & Kaaks, R. (2002). Validity of free testosterone and free estradiol determinations in serum samples from postmenopausal women by theoretical calculations. <em>Cancer Epidemiology and Prevention Biomarkers</em>, <em>11</em>(10), 1065–1071. [<a href="https://scholar.google.com/scholar?cluster=18409886331928026045">Google Scholar</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12376508/">PubMed</a>] [<a href="https://aacrjournals.org/cebp/article/11/10/1065/166164/Validity-of-Free-Testosterone-and-Free-Estradiol">URL</a>]</li>
|
||||
<li>Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999). A critical evaluation of simple methods for the estimation of free testosterone in serum. <em>The Journal of Clinical Endocrinology & Metabolism</em>, <em>84</em>(10), 3666–3672. [DOI:<a href="https://doi.org/10.1210/jcem.84.10.6079">10.1210/jcem.84.10.6079</a>]</li>
|
||||
</ul>]]></content><author><name>{"first_name"=>"Aly", "last_name"=>"W.", "author-link"=>"/about/#aly", "articles-link"=>"/articles-by-author/aly/"}</name></author><category term="github" /><category term="workspace" /><summary type="html"><![CDATA[Supplement: The Interactions of Sex Hormones with Sex Hormone-Binding Globulin and Relevance for Transfeminine Hormone Therapy By Aly | First published July 8, 2020 | Last modified March 14, 2023]]></summary></entry><entry><title type="html">Bicalutamide and its Adoption by the Medical Community for Use in Transfeminine Hormone Therapy</title><link href="https://transfemscience.org/articles/bica-adoption/" rel="alternate" type="text/html" title="Bicalutamide and its Adoption by the Medical Community for Use in Transfeminine Hormone Therapy" /><published>2020-07-01T18:39:00-07:00</published><updated>2024-04-06T00:00:00-07:00</updated><id>https://transfemscience.org/articles/bica-adoption</id><content type="html" xml:base="https://transfemscience.org/articles/bica-adoption/"><![CDATA[<h1 id="bicalutamide-and-its-adoption-by-the-medical-community-for-use-in-transfeminine-hormone-therapy">Bicalutamide and its Adoption by the Medical Community for Use in Transfeminine Hormone Therapy</h1>
|
||||
</ul>]]></content><author><name>{"first_name"=>"Aly", "last_name"=>"W.", "author-link"=>"/about/#aly", "articles-link"=>"/articles-by-author/aly/"}</name></author><category term="github" /><category term="workspace" /><summary type="html"><![CDATA[Supplement: The Interactions of Sex Hormones with Sex Hormone-Binding Globulin and Relevance for Transfeminine Hormone Therapy By Aly | First published July 8, 2020 | Last modified March 14, 2023]]></summary></entry><entry><title type="html">Bicalutamide and its Adoption by the Medical Community for Use in Transfeminine Hormone Therapy</title><link href="https://transfemscience.org/articles/bica-adoption/" rel="alternate" type="text/html" title="Bicalutamide and its Adoption by the Medical Community for Use in Transfeminine Hormone Therapy" /><published>2020-07-01T18:39:00-07:00</published><updated>2025-08-23T00:00:00-07:00</updated><id>https://transfemscience.org/articles/bica-adoption</id><content type="html" xml:base="https://transfemscience.org/articles/bica-adoption/"><![CDATA[<h1 id="bicalutamide-and-its-adoption-by-the-medical-community-for-use-in-transfeminine-hormone-therapy">Bicalutamide and its Adoption by the Medical Community for Use in Transfeminine Hormone Therapy</h1>
|
||||
|
||||
<!-- Supports up to four authors per article currently (author, author2, author3, author4) -->
|
||||
|
||||
<p>By
|
||||
<!-- First author --><a href="/about/#aly">Aly</a><!-- Second author --><!-- Third author --><!-- Fourth author --> | First published July 1, 2020
|
||||
| Last modified April 6, 2024</p>
|
||||
| Last modified August 23, 2025</p>
|
||||
|
||||
<h2 id="abstract--tldr">Abstract / TL;DR</h2>
|
||||
|
||||
|
|
@ -4965,7 +4965,7 @@ Figure 5. Meta-analysis of estradiol concentration-time data from cisgender wome
|
|||
|
||||
<p>In actuality, bicalutamide is most widely used in prostate cancer, in the form of combined androgen blockade with surgical or medical castration, at a dosage of 50 mg/day, whereas the 150 mg/day dosage is used less commonly, in the form of monotherapy (<a href="https://en.wikipedia.org/wiki/Bicalutamide">Wiki</a>). Moreover, only the 50 mg/day dosage is used in the United States, where monotherapy is not approved. Among the published case reports of hepatotoxicity with bicalutamide in men with prostate cancer, half have been at a dose of 50 mg/day and the other half have been at a dose of 80 to 150 mg/day (<a href="https://en.wikipedia.org/wiki/Template:Published_case_reports_of_bicalutamide-associated_liver_injury">Wiki</a>). The two instances of death due to hepatotoxicity with bicalutamide were both at 50 mg/day. There is currently no evidence that the hepatotoxicity of bicalutamide is dose-dependent across its clinically used dosage range (<a href="https://en.wikipedia.org/wiki/Side_effects_of_bicalutamide#Liver_toxicity">Wiki</a>), although employment of the lowest effective dose in transfeminine people nonetheless seems prudent just in case. Hence, in contrast to Lewis and colleague’s claims, a bicalutamide dosage of 50 mg/day is not less than that generally used in prostate cancer, and clearly retains substantial hepatotoxic potential.</p>
|
||||
|
||||
<h3 id="update-5-new-bicalutamide-publications-in-2022-through-2024">Update 5: New Bicalutamide Publications in 2022 Through 2024</h3>
|
||||
<h3 id="update-5-new-bicalutamide-publications-in-2022-through-2025">Update 5: New Bicalutamide Publications in 2022 Through 2025</h3>
|
||||
|
||||
<ul>
|
||||
<li>Angus, L., Nolan, B., Zajac, J., & Cheung, A. (November 2022). Use of bicalutamide as an androgen receptor antagonist in transgender women. <em>ESA/SRB/APEG/NZSE ASM 2022, November 13-16, Christchurch, Abstracts and Programme</em>, 127–127 (abstract no. 280). [<a href="https://esa-srb-apeg-nzse-2022.p.asnevents.com.au/days/2022-11-14/abstract/85266">URL</a>] [<a href="https://files.transfemscience.org/pdfs/Angus%20et%20al.%20(2022)%20-%20Use%20of%20bicalutamide%20as%20an%20androgen%20receptor%20antagonist%20in%20transgender%20women%20(ESA-SRB-APEG-NZSE%20ASM%202022,%20abstract%20no.%20280).pdf">PDF</a>] [<a href="https://www.endocrinesociety.org.au/esa-srb-apeg-nzse-2022-program_abstracts.pdf#page=127">Full Abstract Book</a>]</li>
|
||||
|
|
@ -4978,9 +4978,10 @@ Figure 5. Meta-analysis of estradiol concentration-time data from cisgender wome
|
|||
<li>Vierregger, K., Tetzlaf, M., Zimmerman, B., Dunn, N., Finney, N., Lewis, K., Slomoff, R., & Strutner, S. (November 2023). Bicalutamide Use as Antiandrogen in Trans Feminine Adults - A Safety Profile. <em>USPATH Scientific Symposium, November 1-5, 2023, The Westin Westminster, Westminster, Colorado, Abstract Submissions</em>, 96–96 (abstract no. SAT-B2-T4). [<a href="https://www.wpath.org/media/cms/Upcoming%20Conferences/2023/Schedules/Final%20USPATH%202023%20Scientific%20Symposium%20Main%20Program%20-%20Full%20Schedule.pdf">Symposium Schedule</a>] [<a href="https://files.transfemscience.org/pdfs/Vierregger%20et%20al.%20(2023)%20-%20Bicalutamide%20Use%20as%20Antiandrogen%20in%20Trans%20Feminine%20Adults%20-%20A%20Safety%20Profile%20(USPATH%202023,%20abstract%20no.%20SAT-B2-T4).pdf">PDF</a>] [<a href="https://files.transfemscience.org/pdfs/wpath-symposia-materials/USPATH%202023%20Symposium%20Abstracts.pdf#page=96">Full Abstract Book</a>]</li>
|
||||
<li>Warus, J., Rincon, M. G., Salvetti, B., & Olson-Kennedy, J. (November 2023). Safety of Bicalutamide as Anti-Androgenic Therapy in Gender Affirming Care for Adolescents and Young Adults: A Retrospective Chart Review. <em>USPATH Scientific Symposium, November 1-5, 2023, The Westin Westminster, Westminster, Colorado, Abstract Submissions</em>, 124–124 (abstract no. SUN-B1-T5). [<a href="https://www.wpath.org/media/cms/Upcoming%20Conferences/2023/Schedules/Final%20USPATH%202023%20Scientific%20Symposium%20Main%20Program%20-%20Full%20Schedule.pdf">Symposium Schedule</a>] [<a href="https://files.transfemscience.org/pdfs/Warus%20et%20al.%20(2023)%20-%20Safety%20of%20Bicalutamide%20as%20Anti-Androgenic%20Therapy%20in%20Gender%20Affirming%20Care%20for%20Adolescents%20and%20Young%20Adults_%20A%20Retrospective%20Chart%20Review%20(USPATH%202023,%20abstract%20no.%20SUN-B1-T5).pdf">PDF</a>] [<a href="https://files.transfemscience.org/pdfs/wpath-symposia-materials/USPATH%202023%20Symposium%20Abstracts.pdf#page=124">Full Abstract Book</a>]</li>
|
||||
<li>Wilde, B., Diamond, J. B., Laborda, T. J., Frank, L., O’Gorman, M. A., & Kocolas, I. (2023). Bicalutamide-Induced Hepatotoxicity in a Transgender Male-to-Female Adolescent. <em>Journal of Adolescent Health</em>, <em>74</em>(1), 202–204. [DOI:<a href="https://doi.org/10.1016/j.jadohealth.2023.08.024">10.1016/j.jadohealth.2023.08.024</a>]</li>
|
||||
<li>Burgener, K., DeBosch, B., Wang, J., Lewis, C., & Herrick, C. J. (2024). Bicalutamide does not raise transaminases in comparison to alternative anti-androgen regimens among transfeminine adolescents and young adults: a retrospective cohort study. <em>medRxiv</em>, preprint. [DOI:<a href="https://www.medrxiv.org/content/10.1101/2024.02.21.24302999v1">10.1101/2024.02.21.24302999v1</a>] [<a href="https://www.medrxiv.org/content/medrxiv/early/2024/02/23/2024.02.21.24302999.full.pdf">PDF</a>]</li>
|
||||
<li>Burgener, K., DeBosch, B., Wang, J., Lewis, C., & Herrick, C. (2025). Bicalutamide does not raise transaminases clinically significantly compared to alternative anti-androgen regimens among transfeminine adolescents and young adults: a retrospective cohort study. <em>International Journal of Transgender Health</em>, 1–10. [DOI:<a href="https://doi.org/10.1080/26895269.2025.2452184">10.1080/26895269.2025.2452184</a>]</li>
|
||||
<li>Fuqua, J. S., Shi, E., & Eugster, E. A. (2024). A retrospective review of the use of bicalutamide in transfeminine youth; a single center experience. <em>International Journal of Transgender Health</em>, advance online publication. [DOI:<a href="https://doi.org/10.1080/26895269.2023.2294321">10.1080/26895269.2023.2294321</a>]</li>
|
||||
<li>Shumer, D., & Roberts, S. A. (2024). Placing a Report of Bicalutamide-Induced Hepatotoxicity in the Context of Current Standards of Care for Transgender Adolescents. <em>Journal of Adolescent Health</em>, <em>74</em>(1), 5–6. [DOI:<a href="https://doi.org/10.1016/j.jadohealth.2023.10.010">10.1016/j.jadohealth.2023.10.010</a>]</li>
|
||||
<li>Angus, L. M., Hong, Q. V., Cheung, A. S., & Nolan, B. J. (2024). Effect of bicalutamide on serum total testosterone concentration in transgender adults: a case series. <em>Therapeutic Advances in Endocrinology and Metabolism</em>, <em>15</em>. [DOI:<a href="https://doi.org/10.1177/20420188241305022">10.1177/20420188241305022</a>]</li>
|
||||
</ul>
|
||||
|
||||
<h3 id="update-6-original-bicalutamide-liver-and-lung-toxicity-analysis-by-sam">Update 6: Original Bicalutamide Liver and Lung Toxicity Analysis by Sam</h3>
|
||||
|
|
@ -4999,6 +5000,7 @@ Figure 5. Meta-analysis of estradiol concentration-time data from cisgender wome
|
|||
<li>Anderson, J. (2003). The role of antiandrogen monotherapy in the treatment of prostate cancer. <em>BJU International</em>, <em>91</em>(5), 455–461. [DOI:<a href="https://doi.org/10.1046/j.1464-410X.2003.04026.x">10.1046/j.1464-410X.2003.04026.x</a>]</li>
|
||||
<li>Angus, L., Nolan, B., Zajac, J., & Cheung, A. (2022). Use of bicalutamide as an androgen receptor antagonist in transgender women. <em>ESA/SRB/APEG/NZSE ASM 2022, November 13-16, Christchurch, Abstracts and Programme</em>, 127–127 (abstract no. 280). [<a href="https://esa-srb-apeg-nzse-2022.p.asnevents.com.au/days/2022-11-14/abstract/85266">URL</a>] [<a href="https://files.transfemscience.org/pdfs/Angus%20et%20al.%20(2022)%20-%20Use%20of%20bicalutamide%20as%20an%20androgen%20receptor%20antagonist%20in%20transgender%20women%20(ESA-SRB-APEG-NZSE%20ASM%202022,%20abstract%20no.%20280).pdf">PDF</a>] [<a href="https://www.endocrinesociety.org.au/esa-srb-apeg-nzse-2022-program_abstracts.pdf#page=127">Full Abstract Book</a>]</li>
|
||||
<li>Angus, L. M., Nolan, B. J., Zajac, J. D., & Cheung, A. S. (2023). Bicalutamide as an anti-androgen in trans people: a cross-sectional study. <em>AusPATH 2023 Symposium</em>. [<a href="https://ashm.eventsair.com/QuickEventWebsitePortal/auspath-conference-2023/aus24/Agenda/AgendaItemDetail?id=0c7c2d1d-21c4-4b21-920f-99446f96a548">URL</a>] [<a href="https://az659834.vo.msecnd.net/eventsairaueprod/production-ashm-public/071ac7b75cbe4d35a6fa168110ea3070">PDF</a>] [<a href="https://files.transfemscience.org/pdfs/misc/Angus%20et%20al.%20AUSPATH%202023%20Bicalutamide%20Study%20Slides.pdf">Slides</a>] [<a href="https://www.transresearch.org.au/post/2023_auspath">Trans Health Research Blog Post</a>]</li>
|
||||
<li>Angus, L. M., Hong, Q. V., Cheung, A. S., & Nolan, B. J. (2024). Effect of bicalutamide on serum total testosterone concentration in transgender adults: a case series. <em>Therapeutic Advances in Endocrinology and Metabolism</em>, <em>15</em>. [DOI:<a href="https://doi.org/10.1177/20420188241305022">10.1177/20420188241305022</a>]</li>
|
||||
<li>Arya, V. B., & Davies, J. H. (2019). Idiopathic gonadotropin-independent precocious puberty - is regular surveillance required? <em>Journal of Pediatric Endocrinology & Metabolism: JPEM</em>, <em>32</em>(4), 403–407. [DOI:<a href="https://doi.org/10.1515/jpem-2018-0419">10.1515/jpem-2018-0419</a>]</li>
|
||||
<li>Asscheman, H., Gooren, L. J., & Peereboom-Wynia, J. D. (1989). Reduction in undesired sexual hair growth with anandron in male-to-female transsexuals—experiences with a novel androgen receptor blocker. <em>Clinical and Experimental Dermatology</em>, <em>14</em>(5), 361–363. [DOI:<a href="https://doi.org/10.1111/j.1365-2230.1989.tb02585.x">10.1111/j.1365-2230.1989.tb02585.x</a>]</li>
|
||||
<li>Asscheman, H., & Gooren, L. J. (1992). Hormone Treatment in Transsexuals. In Bocking, W. O., Coleman, E. (Eds). <em>Gender Dysphoria: Interdisciplinary Approaches in Clinical Management</em> (pp. 39–54). Binghamton: Haworth Press. / <em>Journal of Psychology & Human Sexuality</em>, <em>5</em>(4), 39–54. [<a href="https://scholar.google.com/scholar?cluster=3926911364428297742">Google Scholar</a>] [<a href="https://books.google.com/books?id=fny-DwAAQBAJ&pg=PT38">Google Books</a>] [DOI:<a href="https://doi.org/10.1300/J056v05n04_03">10.1300/J056v05n04_03</a>]</li>
|
||||
|
|
@ -5010,7 +5012,7 @@ Figure 5. Meta-analysis of estradiol concentration-time data from cisgender wome
|
|||
<li>Bambilla, A., Beal, C., & Vigil, P. (2023). Improving Access to Bicalutamide in Gender Affirming Medical Care. [Unpubished/pending publication] [<a href="https://www.queercme.com/blog/bicalutamide-prescribing-in-gender-affirming-care">QueerCME Blog Post</a>]</li>
|
||||
<li>Blackledge, G. R. P. (1996). Clinical progress with a new antiandrogen, Casodex™ (bicalutamide). <em>European Urology</em>, <em>29</em>(Suppl 2), 96–104. [DOI:<a href="https://doi.org/10.1159/000473847">10.1159/000473847</a>]</li>
|
||||
<li>Burgener, K., DeBosch, B., Lewis, C., Wallendorf, M., & Herrick, C. (2023). Assessment of Liver Function and Toxicity in Transgender Female Adolescents Prescribed Bicalutamide. <em>Hormone Research in Paediatrics</em>, <em>96</em>(Suppl 3 [<em>Abstracts of the 2023 Pediatric Endocrine Society (PES) Annual Meeting’ to Hormone Research in Paediatrics</em>]), 377–378 (abstract no. 6232). [DOI:<a href="https://doi.org/10.1159/000531602">10.1159/000531602</a>] [<a href="https://files.transfemscience.org/pdfs/Burgener%20et%20al.%20(2023)%20-%20Assessment%20of%20Liver%20Function%20and%20Toxicity%20in%20Transgender%20Female%20Adolescents%20Prescribed%20Bicalutamide%20(PES%202023,%20abstract%20ID%206232).pdf">PDF</a>]</li>
|
||||
<li>Burgener, K., DeBosch, B., Wang, J., Lewis, C., & Herrick, C. J. (2024). Bicalutamide does not raise transaminases in comparison to alternative anti-androgen regimens among transfeminine adolescents and young adults: a retrospective cohort study. <em>medRxiv</em>, preprint. [DOI:<a href="https://www.medrxiv.org/content/10.1101/2024.02.21.24302999v1">10.1101/2024.02.21.24302999v1</a>] [<a href="https://www.medrxiv.org/content/medrxiv/early/2024/02/23/2024.02.21.24302999.full.pdf">PDF</a>]</li>
|
||||
<li>Burgener, K., DeBosch, B., Wang, J., Lewis, C., & Herrick, C. (2025). Bicalutamide does not raise transaminases clinically significantly compared to alternative anti-androgen regimens among transfeminine adolescents and young adults: a retrospective cohort study. <em>International Journal of Transgender Health</em>, 1–10. [DOI:<a href="https://doi.org/10.1080/26895269.2025.2452184">10.1080/26895269.2025.2452184</a>]</li>
|
||||
<li>Cocchetti, C., Ristori, J., Romani, A., Maggi, M., & Fisher, A. D. (2020). Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals. <em>Journal of Clinical Medicine</em>, <em>9</em>(6), 1609. [DOI:<a href="https://doi.org/10.3390/jcm9061609">10.3390/jcm9061609</a>]</li>
|
||||
<li>Coleman, E., Radix, A. E., Bouman, W. P., Brown, G. R., de Vries, A. L., Deutsch, M. B., Ettner, R., Fraser, L., Goodman, M., Green, J., Hancock, A. B., Johnson, T. W., Karasic, D. H., Knudson, G. A., Leibowitz, S. F., Meyer-Bahlburg, H. F., Monstrey, S. J., Motmans, J., Nahata, L., … & Arcelus, J. (2022). [World Professional Association for Transgender Health (WPATH)] Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. <em>International Journal of Transgender Health</em>, <em>23</em>(Suppl 1), S1–S259. [DOI:<a href="https://doi.org/10.1080/26895269.2022.2100644">10.1080/26895269.2022.2100644</a>] [<a href="https://www.wpath.org/publications/soc">URL</a>] [<a href="https://www.tandfonline.com/doi/pdf/10.1080/26895269.2022.2100644">PDF</a>]</li>
|
||||
<li>Dahl, M., Feldman, J. L., Goldberg, J. M., & Jaberi, A. (2006). Physical aspects of transgender endocrine therapy. <em>International Journal of Transgenderism</em>, <em>9</em>(3–4), 111–134. [DOI:<a href="https://doi.org/10.1300/J485v09n03_06">10.1300/J485v09n03_06</a>]</li>
|
||||
|
|
@ -5081,4 +5083,4 @@ Figure 5. Meta-analysis of estradiol concentration-time data from cisgender wome
|
|||
<li>Vierregger, K., Tetzlaf, M., Zimmerman, B., Dunn, N., Finney, N., Lewis, K., Slomoff, R., & Strutner, S. (2023). Bicalutamide Use as Antiandrogen in Trans Feminine Adults - A Safety Profile. <em>USPATH Scientific Symposium, November 1-5, 2023, The Westin Westminster, Westminster, Colorado, Abstract Submissions</em>, 96–96 (abstract no. SAT-B2-T4). [<a href="https://www.wpath.org/media/cms/Upcoming%20Conferences/2023/Schedules/Final%20USPATH%202023%20Scientific%20Symposium%20Main%20Program%20-%20Full%20Schedule.pdf">Symposium Schedule</a>] [<a href="https://files.transfemscience.org/pdfs/Vierregger%20et%20al.%20(2023)%20-%20Bicalutamide%20Use%20as%20Antiandrogen%20in%20Trans%20Feminine%20Adults%20-%20A%20Safety%20Profile%20(USPATH%202023,%20abstract%20no.%20SAT-B2-T4).pdf">PDF</a>] [<a href="https://files.transfemscience.org/pdfs/wpath-symposia-materials/USPATH%202023%20Symposium%20Abstracts.pdf#page=96">Full Abstract Book</a>]</li>
|
||||
<li>Warus, J., Rincon, M. G., Salvetti, B., & Olson-Kennedy, J. (2023). Safety of Bicalutamide as Anti-Androgenic Therapy in Gender Affirming Care for Adolescents and Young Adults: A Retrospective Chart Review. <em>USPATH Scientific Symposium, November 1-5, 2023, The Westin Westminster, Westminster, Colorado, Abstract Submissions</em>, 124–124 (abstract no. SUN-B1-T5). [<a href="https://www.wpath.org/media/cms/Upcoming%20Conferences/2023/Schedules/Final%20USPATH%202023%20Scientific%20Symposium%20Main%20Program%20-%20Full%20Schedule.pdf">Symposium Schedule</a>] [<a href="https://files.transfemscience.org/pdfs/Warus%20et%20al.%20(2023)%20-%20Safety%20of%20Bicalutamide%20as%20Anti-Androgenic%20Therapy%20in%20Gender%20Affirming%20Care%20for%20Adolescents%20and%20Young%20Adults_%20A%20Retrospective%20Chart%20Review%20(USPATH%202023,%20abstract%20no.%20SUN-B1-T5).pdf">PDF</a>] [<a href="https://files.transfemscience.org/pdfs/wpath-symposia-materials/USPATH%202023%20Symposium%20Abstracts.pdf#page=124">Full Abstract Book</a>]</li>
|
||||
<li>Wilde, B., Diamond, J. B., Laborda, T. J., Frank, L., O’Gorman, M. A., & Kocolas, I. (2023). Bicalutamide-Induced Hepatotoxicity in a Transgender Male-to-Female Adolescent. <em>Journal of Adolescent Health</em>, <em>74</em>(1), 202–204. [DOI:<a href="https://doi.org/10.1016/j.jadohealth.2023.08.024">10.1016/j.jadohealth.2023.08.024</a>]</li>
|
||||
</ul>]]></content><author><name>{"first_name"=>"Aly", "last_name"=>"W.", "author-link"=>"/about/#aly", "articles-link"=>"/articles-by-author/aly/"}</name></author><category term="github" /><category term="workspace" /><summary type="html"><![CDATA[Bicalutamide and its Adoption by the Medical Community for Use in Transfeminine Hormone Therapy By Aly | First published July 1, 2020 | Last modified April 6, 2024]]></summary></entry></feed>
|
||||
</ul>]]></content><author><name>{"first_name"=>"Aly", "last_name"=>"W.", "author-link"=>"/about/#aly", "articles-link"=>"/articles-by-author/aly/"}</name></author><category term="github" /><category term="workspace" /><summary type="html"><![CDATA[Bicalutamide and its Adoption by the Medical Community for Use in Transfeminine Hormone Therapy By Aly | First published July 1, 2020 | Last modified August 23, 2025]]></summary></entry></feed>
|
||||
Loading…
Add table
Reference in a new issue